share_log

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $9 Price Target

Benzinga ·  Jan 31 12:38

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $9 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 363

Recommended

Write a comment